What is the appropriate management for allergic conjunctivitis?

Management of Allergic Conjunctivitis

Start with topical antihistamine/mast cell stabilizer combination agents as first-line therapy, escalating to short-course topical corticosteroids (1-2 weeks) if symptoms remain uncontrolled, while implementing allergen avoidance and cool compresses as foundational measures 1.

Stepwise Treatment Algorithm

Step 1: Conservative Measures + First-Line Pharmacotherapy

Begin all patients with:

• Environmental modifications: Allergen avoidance, hand hygiene, hypoallergenic bedding, frequent clothes washing, showering before bedtime
• Cool compresses and refrigerated preservative-free artificial tears to dilute allergens and inflammatory mediators on the ocular surface 1
• Topical dual-action agents (antihistamine + mast cell stabilizer) - these are more effective than older generation antihistamine/vasoconstrictor combinations and can be used for both acute and chronic disease 1, 2

Critical caveat: Avoid chronic vasoconstrictor use due to rebound vasodilation 2. Avoid punctal plugs as they prevent flushing of allergens and inflammatory mediators 2.

Step 2: Inadequate Control - Add Topical Corticosteroids

If symptoms persist despite first-line therapy:

• Brief course (1-2 weeks) of topical corticosteroids with low side effect profile 1
• This is the appropriate escalation for seasonal/perennial allergic conjunctivitis not responding to antihistamines and mast cell stabilizers

Important monitoring: If corticosteroids are used chronically or recurrently, perform baseline and periodic IOP measurement and pupillary dilation to evaluate for glaucoma and cataract 1, 2.

Step 3: Severe or Refractory Cases

For severe disease unresponsive to the above:

• Topical cyclosporine 0.05% (at least four times daily) or tacrolimus 1
• These immunomodulators allow for reduced steroid use and are effective for severe cases

Warning: These agents may increase susceptibility to herpes simplex keratitis 1.

Oral Antihistamines: Use With Caution

Oral antihistamines are commonly used but may induce or worsen dry eye syndrome and impair the tear film's protective barrier 1. If used, concomitant preservative-free artificial tears are essential 1.

Special Considerations for Vernal Keratoconjunctivitis (VKC)

This severe variant requires more aggressive management:

• Topical corticosteroids are usually necessary for acute exacerbations 1
• Cyclosporine 0.1% is FDA-approved specifically for VKC in children and adults 1
• For sight-threatening VKC unresponsive to topical therapy, consider supratarsal corticosteroid injection 1

Atopic Conjunctivitis Management

Follow the same stepwise approach, with additional consideration for:

• Eyelid involvement: Treat with pimecrolimus cream 1% or tacrolimus ointment 0.03% (ages 2-15) or 0.03-0.1% (ages 16+) 1
• Tacrolimus 0.1% applied conjunctivally has demonstrated efficacy in patients who failed corticosteroids, cyclosporine, and antiallergy medications 1

Critical Pitfall: Keratoconus Risk

Allergic conjunctivitis and atopic disease are associated with keratoconus. Adequate control of allergy and prevention of eye rubbing are essential to decrease progression of ectasia 1, 2. This makes aggressive symptom control particularly important beyond just comfort.

When to Refer to Allergist

Consider allergen-specific immunotherapy (subcutaneous or sublingual) for patients whose disease cannot be adequately controlled with topical medications and oral antihistamines 2. While effective, usage may be limited by expense, long-term commitment, and anaphylaxis risk.

Follow-Up Strategy

Base frequency on disease severity, etiology, and treatment. During follow-up:

• Interval history
• Visual acuity measurement
• Slit-lamp biomicroscopy
• If on chronic/recurrent corticosteroids: IOP monitoring and dilated exam for cataract evaluation 1, 2

The 2024 Ophthalmology guidelines 1 represent the most current evidence-based approach, emphasizing the stepwise escalation from conservative measures and dual-action topical agents to corticosteroids, with immunomodulators reserved for severe or refractory cases.